Sidgiddi, S., U. Ranganathan, and A. Gautam. “DFD-03 (0.1% Tazarotene), Twice-Daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product With Once-Daily Overnight Application”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s46, doi:10.25251/skin.1.supp.45.